Showing results (111-120 of 217) with videos related to
Sort By:
Pageof 22
Annals of the Rheumatic Diseases|March 19, 2013
Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results from the European Prospective Investigation of Cancer-Norfolk and the Norfolk Arthritis Register--the EPIC-2-NOAR Study)Manjari Lahiri, Robert N Luben, Catharine Morgan, et al.Cells|February 23, 2024
Novel Glycomimetics Protect against Glycated Low-Density Lipoprotein-Induced Vascular Calcification In Vitro via Attenuation of the RAGE/ERK/CREB PathwayGary P Sidgwick, Ria Weston, Ayman M Mahmoud, et al.Clinical and Experimental Rheumatology|October 18, 2012
Treat-to-target in systemic lupus erythematosus: where are we today?Marta Mosca, Dimitrios T Boumpas, Ian N Bruce, et al.The Journal of Rheumatology|September 3, 2010
The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosusKathleen McElhone, Madhura Castelino, Janice Abbott, et al.Annals of the Rheumatic Diseases|May 17, 2022
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trialsIan N Bruce, Richard A Furie, Eric F Morand, et al.Annals of the Rheumatic Diseases|March 26, 2022
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trialsEdward M Vital, Joan T Merrill, Eric F Morand, et al.Arthritis & Rheumatology (Hoboken, N.J.)|December 30, 2025
Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP-SC StudySusan Manzi, Ian N Bruce, Eric F Morand, et al.Arthritis & Rheumatology (Hoboken, N.J.)|November 21, 2022
Gene Expression and Autoantibody Analysis Revealing Distinct Ancestry-Specific Profiles Associated With Response to Rituximab in Refractory Systemic Lupus ErythematosusLucy M Carter, Adewonuola Alase, Zoe Wigston, et al.Rheumatology and Therapy|April 5, 2025
Disease-Modifying Therapies in Lupus Nephritis: A Narrative Review Evaluating Currently Used Pharmacologic AgentsAnca D Askanase, Richard Furie, Maria Dall'Era, et al.Arthritis Research & Therapy|February 8, 2019
Rheumatoid arthritis reprograms circadian output pathwaysToryn M Poolman, Julie Gibbs, Amy L Walker, et al.Pageof 22